Skip to content

A comparative study for the effect of Wen-Yang Hua-Ji method of Chinese medicine in the treatment of membranous nephropathy

The bidirectional cohort study on the correlation between the efficacy of Wenyang Huaji method and membranous nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035234
Enrollment
Unknown
Registered
2020-08-04
Start date
2020-08-04
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous Nephropathy

Interventions

Sponsors

Beijing Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 75 years old; 2. The patients who met the diagnostic criteria of Western medicine for membranous nephropathy, and met the requirement that the 24-hour urine protein quantity of the enrolled patients was still more than 5g after 12 weeks of follow-up (i.e., they could not spontaneously relieve); 3. Patients who meet the diagnostic criteria of syndrome accumulation of Yang deficiency syndrome in TCM; 4. Patients who have signed informed consent form; 5. Ckd1-3, EGFR (EPI formula) >=40ml / min, serum albumin > 15g / L.

Exclusion criteria

Exclusion criteria: 1. Patients with progressive membranous nephropathy (progressive decline of renal function; necrotizing capillary inflammation and > 50% crescentic formation) in renal biopsy, accompanied with IgA nephropathy, diabetic nephropathy and other kidney diseases; 2. Patients with abnormal antinuclear antibody, double stranded DNA, ANCA or other immune diseases; 3. Patients with active hepatitis B and abnormal transaminase in continuous liver function test; Patients with history of HIV / AIDS, severe gastrointestinal cancer, or history of central nervous system malignancy; 4; 5. Patients with life-threatening complications such as severe infection or severe diseases and dysfunction of other organs; 6. The subjects known to be allergic to the components of the traditional Chinese medicine granules used; 7. Pregnant or lactating women; 8. Subjects undergoing other clinical trials.

Design outcomes

Primary

MeasureTime frame
Anti-PLA2R Antibody;24-hour urine protein;Blood albumin;TCM syndrome scores;

Secondary

MeasureTime frame
Serum creatinine;Blood urea nitrogen;Total Cholesterol;Triglyceride;

Countries

China

Contacts

Public ContactLiu Baoli

Beijing Hospital of traditional Chinese Medicine Affiliated to Capital Medical University

polyliu2000@sina.com+86 18901051212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026